Updated:
Zhongchao Inc.
Zhongchao Inc. (ZCMD) is a Chinese healthcare platform providing medical education and clinical support to physicians through Zhongchao Medical Technology.
Zhongchao Inc.
Zhongchao Inc. was founded in 2018 and is headquartered in Shanghai, China. The company went public on the Nasdaq in 2021 under the ticker ZCMD, raising approximately $20 million in its initial public offering (per SEC filings, 2021). Its core business revolves around Zhongchao Medical Technology, a mobile platform that provides medical education, clinical guidelines, and drug information to Chinese doctors. Revenue is driven by subscription services, advertising, and data analytics for pharmaceutical companies. The firm's strategy centers on digital healthcare services in China, targeting the physician education market. It competes with platforms like DXY and Haodf. Zhongchao has not reported significant operating profitability since its IPO, with net losses in fiscal years 2022 and 2023 (per annual reports). The company maintains a lean corporate structure with a small executive team, though specific investment operations are not publicly detailed. No additional offices or philanthropic vehicles are disclosed. Zhongchao Inc. is primarily a healthcare technology company, not a family office or asset manager. Its investment activities, if any, are minimal and not publicly reported.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What does Zhongchao Inc. actually do?
Zhongchao operates a digital platform for Chinese healthcare professionals. It offers online medical education courses, clinical decision support tools, and drug reference databases. Revenue comes from subscription fees paid by doctors and advertising from pharmaceutical companies. The company went public on Nasdaq in 2021.
Is Zhongchao Inc. a family office or investment firm?
No. The company is a publicly traded healthcare technology firm classified as an asset manager by some data services, but its core business is digital healthcare services. It does not manage third-party capital or operate as a family office. Any investment activities are incidental to its primary medical education operations.
How does Zhongchao generate revenue?
The company primarily earns revenue through subscription fees from healthcare professionals who use its educational platform, as well as advertising revenue from pharmaceutical and medical device companies targeting those professionals. It also provides data analytics services to pharmaceutical clients (per SEC filings).
What is Zhongchao's financial performance?
The company has reported net losses since its 2021 IPO. For fiscal year 2022, it posted a net loss of $3.2 million on revenue of $8.9 million (per 20-F filing). It has not disclosed profitability targets or significant cash reserves.
Who are Zhongchao's main competitors?
Zhongchao competes with other Chinese digital healthcare platforms, including DXY (a leading medical community for doctors) and Haodf (an online healthcare services platform). It also faces competition from traditional medical education providers in China.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: